PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

April 20, 2023

Primary Completion Date

November 1, 2024

Study Completion Date

December 11, 2024

Conditions
Ventilator Associated Pneumonia
Interventions
DRUG

BV100 plus Polymyxin B

Rifabutin for Infusion plus Polymyxin B for Injection

DRUG

BAT

The best avaialble antibiotic therapy to treat CRAB

Trial Locations (16)

Unknown

Academician Vakhtang Bochorishvili Clinic, Tbilisi

Eristavi National Center of Experimental and Clinical Surgery, Tbilisi

First University Clinic of Tbilisi State Medical University, Tbilisi

Gudushauri National Medical Center, Tbilisi

Malkhaz Katsiashvili Multiprofile Emergency Medicine Center, Tbilisi

Number 5 Clinical Hospital, Tbilisi

Tbilisi State Medical University and Ingorokva High Medical Technology University Clinic, Tbilisi

"General Hospital of Athens Evangelismos", Athens

"University General Hospital Attikon", Athens

General University Hospital of Heraklion, Heraklion

General Hospital of Larissa, Larissa

University General Hospital of Larissa, Larissa

"General Hospital of Thessaloniki Ippokratio", Thessaloniki

University of Debrecen Clinical Center, Debrecen

University Educational Hospital, Miskolc

Fejer County St. Gyorgy University Teaching Hospital, Székesfehérvár

Sponsors

Lead Sponsor

All Listed Sponsors
lead

BioVersys AG

INDUSTRY

NCT05685615 - PK of BV100 in Patients VABP Suspected or Confirmed to Be Due to CRAB | Biotech Hunter | Biotech Hunter